Related Experiment Video
Updated: May 5, 2026
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
9.3K
[MicroRNA in neurodegenerative disorders]
1Department of Neurology, Nagoya University Graduate School of Medicine.
Rinsho Shinkeigaku = Clinical Neurology
|December 3, 2013
Summary
MicroRNAs (miRNAs) can treat neurodegenerative diseases like spinal and bulbar muscular atrophy (SBMA). This study shows miR-196a therapy reduces mutant androgen receptor (AR) in SBMA mice, mitigating motor neuron loss.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Context:
- MicroRNAs (miRNAs) regulate gene expression by targeting mRNA, influencing various cellular processes.
- Neurodegenerative diseases, including spinal and bulbar muscular atrophy (SBMA), are linked to altered gene expression and protein aggregation.
- SBMA is caused by polyglutamine expansion in the androgen receptor (AR), leading to motor neuron degeneration.
Purpose:
- To investigate the role of miR-196a in the pathogenesis of SBMA.
- To explore the therapeutic potential of miR-196a delivery for SBMA treatment.
Summary:
- This study found elevated miR-196a levels in an SBMA mouse model.
- miR-196a was shown to degrade mutant AR mRNA by targeting CUG triplet repeat RNA binding protein 2, which stabilizes mutant AR.
- Adeno-associated virus-mediated delivery of miR-196a reduced mutant AR expression and mitigated motor neuron degeneration in SBMA mice.
Impact:
- MicroRNA-based therapies offer a novel strategy for treating neurodegenerative diseases.
- This research highlights miR-196a as a potential therapeutic agent for SBMA.
- The findings contribute to understanding miRNA-mediated gene regulation in neurodegeneration.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:22MicroRNAs
21.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:22MicroRNAs
9.8K
9.8K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29